PYC Therapeutics Limited Share Price
Stocks
PYC
AU000000PYC7
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Australian S.E.
11:41:58 08/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 2.500 AUD | -0.40% |
|
+9.17% | +51.06% |
| 04/09 | PYC Therapeutics Limited - Special Call | |
| 03/09 | ASX Biggest Gainers | MT |
| Market Cap | 246.86Cr 178.19Cr 153.24Cr 144.13Cr 131.57Cr 246.06Cr 17TCr 1.71TCr 660.56Cr 8.63TCr 669.17Cr 654.54Cr 27TCr | P/E 2027 * |
-32.7x | P/E 2028 * | -30.7x |
|---|---|---|---|---|---|
| Enterprise Value | 187.05Cr 135.02Cr 116.12Cr 109.21Cr 100Cr 186.45Cr 13TCr 1.29TCr 500.52Cr 6.54TCr 507.05Cr 495.96Cr 21TCr | EV / Sales 2027 * |
-
| EV / Sales 2028 * | - |
| Free-Float |
67.03% | Yield 2027 * |
-
| Yield 2028 * | - |
| Markets | Quality | ||
|---|---|---|---|
Australian S.E.
| PYC | Delayed | |
OTC Markets
| PYCXF | Delayed |
Last Transcript : PYC Therapeutics Limited
| 17/03 | Bell Potter rates PYC as Speculative Buy | AQ |
| 09/25/09 | Bell Potter rates PYC as Speculative Buy | AQ |
| 07/24/07 | PYC Therapeutics : Anti Bribery & Anti Corruption Policy | PU |
| 07/24/07 | PYC Therapeutics : Definition of Independence | PU |
| 07/24/07 | PYC Therapeutics : Continuous Disclosure Policy | PU |
| 1 day | -0.40% | ||
| 1 week | +9.17% | ||
| Current month | +7.76% | ||
| 1 month | +19.62% | ||
| 3 months | +109.21% | ||
| 6 months | +68.92% | ||
| Current year | +51.06% |
| 1 week | 2.27 |  | 2.62 |
| 1 month | 2.02 | | 2.62 |
| Current year | 1.04 | | 2.62 |
| 1 year | 0.85 | | 2.62 |
| 3 years | 0.52 | | 2.62 |
| 5 years | 0.5 | | 2.62 |
| 10 years | 0.15 | | 2.62 |
| Manager | Title | Age | Since |
|---|---|---|---|
Rohan Hockings
CEO | Chief Executive Officer | 42 | 19/08/2020 |
Thomas Ulmer
DFI | Director of Finance/CFO | 47 | 07/07/2026 |
Candice Junge
CTO | Chief Tech/Sci/R&D Officer | - | 01/08/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Rohan Hockings
BRD | Director/Board Member | 42 | 30/11/2018 |
Ian Constable
BRD | Director/Board Member | - | 22/09/2025 |
Peter Coleman
CHM | Chairman | 66 | 18/11/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 13/08/26 | Free | Chief Executive Officer | 45,98,662 | 0.4676% | ||
| 13/08/26 | Free | Chief Executive Officer | 1,04,77,965 | 1.0654% | ||
| 13/08/26 | Free | Chief Executive Officer | 77,06,503 | 0.7836% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.40% | +9.17% | +98.41% | +346.43% | 178.19Cr | |
| -0.43% | -3.46% | -2.17% | +15.30% | 4.84TCr | |
| -0.40% | +2.16% | +418.57% | +554.47% | 4.5TCr | |
| -1.42% | +2.52% | +42.67% | +22.27% | 4.41TCr | |
| -1.22% | -0.37% | +4.82% | +84.42% | 4.07TCr | |
| -0.96% | -1.38% | +15.75% | +45.91% | 3.32TCr | |
| -0.21% | +2.86% | - | - | 1.78TCr | |
| -0.35% | -0.45% | +21.42% | +117.63% | 1.65TCr | |
| -0.45% | -0.45% | +11.45% | +31.49% | 1.45TCr | |
| -1.65% | +0.09% | +75.93% | +41.15% | 1.38TCr | |
| Average | -0.76% | +1.08% | +76.32% | +139.90% | 2.76TCr | |
| Weighted average by Cap. | -0.81% | +0.03% | +89.46% | +136.56% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -8.18Cr -5.91Cr -5.08Cr -4.78Cr -4.36Cr -8.16Cr -558.64Cr -57Cr -22Cr -286.08Cr -22Cr -22Cr -911.25Cr | -8.22Cr -5.93Cr -5.1Cr -4.8Cr -4.38Cr -8.19Cr -561.12Cr -57Cr -22Cr -287.35Cr -22Cr -22Cr -915.29Cr |
| Net Debt | -60Cr -43Cr -37Cr -35Cr -32Cr -60Cr -4.08TCr -414.02Cr -160.03Cr -2.09TCr -162.12Cr -158.58Cr -6.66TCr | -53Cr -38Cr -33Cr -31Cr -28Cr -53Cr -3.63TCr -367.86Cr -142.19Cr -1.86TCr -144.05Cr -140.9Cr -5.92TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/26/08 | A$2.500 | -0.40% | 30,14,564 |
| 07/26/07 | A$2.510 | +0.80% | 33,01,375 |
| 04/26/04 | A$2.490 | -3.11% | 33,47,904 |
| 03/26/03 | A$2.570 | +5.76% | 39,92,122 |
| 02/26/02 | A$2.430 | +6.11% | 1,07,51,807 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PYC Stock
Select your edition
All financial news and data tailored to specific country editions
